Pulmonology

Annual Hawaii Cancer Conference

41st Annual CFS®: Innovative Cancer Therapy for Tomorrow

18th Annual New York Lung Cancers Symposium®

22nd Annual Winter Lung Cancer Conference®

Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…

21st Annual Winter Lung Cancer Conference® In Line Session: Advent of TROP2-Directed ADCs In Lung Cancer

Targeted Therapies of Lung Cancer Meeting Satellite Symposia

LIVE! Testing Board®: Breaking Down Pathologic Reports to Identify Actionable Markers in Patients with NSCLC

Community Practice Connections™: The 2nd Annual Hawaii Lung Cancers Conference®

Tissue Stewardship and the Evolving Role of Genomic Alterations in Providing Precision NSCLC Care

Charting the Path to Precision Diagnosis: Detection and Treatment Approaches for Oncogenic Mutations in NSCLC

Community Practice Connection™: 21st Annual Winter Lung Cancer Conference®

Revolutionizing Early-Stage NSCLC Treatment: Pathologists’ Key Insights Into Predicting Pathologic Responses to Immunotherapies

BURST CME™: How Are Emerging Biomarkers and Testing Methodologies Shaping Personalized Medicine in NSCLC?

Navigating Current State-of-the Art NSCLC Patient Care From the Front Lines: Essentials for Oncology Nurses Today and Tomorrow

Medical Crossfire®: How Can Thoracic Teams Facilitate Optimized Care of Patients With Stage I-III EGFR Mutation-Positive NSCLC?

Top 10 Oncogenic Drivers in NSCLC for 2024: Where Are We and Where Are We Going?

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

DLL3 as a Therapeutic Target in SCLC and Beyond: Rationale, Recent Data and Potential for Transformations in Care with T-Cell Engagers

Lung Cancer Tumor Board®: How Do Emerging Data for ICIs, BiTEs, ADCs, and Targeted Strategies Address Unmet Needs in the Therapeutic Continuum for SCLC?

26th Annual International Lung Cancer Congress®

Surv.AI Says: Real-World Insights Into the Journey for Patients With Pulmonary Arterial Hypertension

Advances In™: Moving Care Forward in SCLC with DLL3 Targeting Bispecific T-Cell Engagers

Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management

What’s Next for HER2- and TROP2-Directed ADCs in Lung Cancer: How Emerging Trial Data will Impact our Clinics Today, and Tomorrow….

Do We Have Sea Change in Small Cell Lung Cancer? What Recent Clinical Trial Data Tell Us About Treatment Decision-Making in Real-World Settings, What’s Next for Emerging Novel Strategies

Community Practice Connections™: 25th Annual International Lung Cancer Congress

Community Practice Connections™: 8th Annual School of Nursing Oncology™

Lung Cancer Tumor Board: Enhancing Precision Medicine in NSCLC Through Advancements in Molecular Testing and Optimal Therapy Selection

(CME Credit Only) Lung Cancer Tumor Board®: The Pivotal Role of Multimodal Therapy in Leveraging Immunotherapy for Stage I-III NSCLC When the Goal Is Cure